<p>Annemieke Aartsma-Rus and Elizabeth Vroom discuss with Patricia Lobo the developments in Duchenne muscular dystrophy therapy and how this can serve as a paradigm for development of treatment for rare diseases.</p>

Annemieke Aartsma-Rus and Elizabeth Vroom discuss with Patricia Lobo the developments in Duchenne muscular dystrophy therapy and how this can serve as a paradigm for development of treatment for rare diseases.

Stakeholder cooperation in orphan drug development: The Lancet Neurology: June 6, 2016

The Lancet Neurology is a monthly journal, renowned for the publication of high-quality peer-reviewed research, reviews, and analysis from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue, with occasional interviews with an author of a key article.

Share Stakeholder cooperation in orphan drug development: The Lancet Neurology: June 6, 2016

Sign up to save your podcasts

Stakeholder cooperation in orphan drug development: The Lancet Neurology: June 6, 2016

Stakeholder cooperation in orphan drug development: The Lancet Neurology: June 6, 2016